Akademik Veri Yönetim Sistemi
GAZI MEDICAL JOURNAL, cilt.24, sa.1, ss.1-4, 2013 (ESCI)
Objective: The aim of this study was to evaluate imipenem, meropenem, colistin, amikacin and fosfomycin susceptibilities of multidrug resistant Acinetobacter baumannii clinical isolates. Methods: Fifty multidrug resistant A. baumannii strains isolated from various clinical specimens were enrolled to this study. Bacterial identification was made by using conventional methods and API-20 NE (bioMerieux SA, France) system. The minimum inhibitory concentration (MIC) values of imipenem, meropenem, colistin and amikacin were determined by broth microdilution method by using cation adjusted Mueller Hinton broth, and the MICs of fosfomycin were determined by agar dilution method using Mueller Hinton agar supplemented with 25 mg/L glucose-6-phosphate according to Clinical and Laboratory Standarts Institude (CLSI) recommendations. As CLSI criteria for the determination of fosfomycin susceptibility of A. baumannii are not available, results were interpreted by using the susceptibility ranges of Escherichia coli strains isolated from urinary tract infections. Results: 46 (92%) isolates were resistant to imipenem, and 48 (96%) were resistant to meropenem. All isolates resistant to imipenem were also resistant to meropenem. Two isolates (4%) were intermediate susceptible to imipenem and resistant to meropenem. All isolates except two were susceptible to colistin. 43 isolates (86%) were resistant to amikacin. None of the isolates were susceptible to fosfomycin. The MIC50 values for imipenem, meropenem, colistin, amikacin and fosfomycin were 32 mg/L, 32mg/L, 0,5 mg/L, >128 mg/L, and >512 mg/L, respectively. Conclusion: The most effective antimicrobial agent included in this study against multidrug resistant A. baumannii isolates was colistin. Although fosfomycin is an active agent against certain multidrug resistant bacteria, the use of this agent as monotherapy is not appropriate for multidrug resistant A. baumannii infections.